Eva Sticova1, Alena Lodererova2, Evita van de Steeg3, Sona Frankova4, Marek Kollar2, Vera Lanska5, Radana Kotalova6, Tomas Dedic6, Alfred H Schinkel7, Milan Jirsa8. 1. Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine 14021 Prague 4, Czech Republic ; Third Faculty of Medicine, Charles University 10000 Prague 10, Czech Republic. 2. Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine 14021 Prague 4, Czech Republic. 3. The Netherlands Cancer Institute Amsterdam, The Netherlands ; TNO Zeist, The Netherlands. 4. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine 14021 Prague 4, Czech Republic. 5. Medical Statistics Unit, Institute for Clinical and Experimental Medicine 14021 Prague 4, Czech Republic. 6. 2nd Department of Pediatrics of The 2nd Medical School, Charles University Prague, Czech Republic. 7. The Netherlands Cancer Institute Amsterdam, The Netherlands. 8. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine 14021 Prague 4, Czech Republic.
Abstract
AIM: Organic anion-transporting polypeptides OATP1B1 and OATP1B3 are sinusoidal membrane transporters mediating liver uptake of a wide range of substrates including conjugated and unconjugated bilirubin, xenobiotics and drugs. Absence of OATP1Bs in the liver causes Rotor syndrome. Our aim was to correlate OATP1B expression with hyperbilirubinemia in common liver diseases. METHODS: Immunoreactivity of five antibodies against human OATP1Bs was tested on frozen and formalin-fixed paraffin-embedded liver tissue of mouse strains transgenic for SLCO1B1 or SLCO1B3 and on human specimens. The proportion of hepatocytes expressing OATP1Bs was then assessed immunohistologically in formalin-fixed paraffin-embedded liver samples obtained from patients with hepatocellular and primary biliary liver diseases. UGT1A1 promoter TATA-box and SLCO1B1 rs4149056 genotyping was performed to rule out individuals predisposed to hyperbilirubinemia. RESULTS: The most specific detection of OATP1B3 was achieved with the H-52 (sc-98981) antibody. OATP1B1 was specifically recognized with the ESL (ab15441) anti-OATP1B1 antibody, but only in frozen sections. The MDQ (ab15442) anti-OATP1B1 antibody cross-reacted with both OATP1B proteins in liver tissue of the transgenic mouse strains. Expression of the OATP1B proteins was decreased in advanced liver diseases and inversely correlated with serum bilirubin levels. The reduction was more pronounced in advanced primary biliary diseases (1.9±1.1 vs. 2.7±0.6; P=0.009). CONCLUSIONS: Down-regulation of OATP1B proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases.
AIM: Organic anion-transporting polypeptides OATP1B1 and OATP1B3 are sinusoidal membrane transporters mediating liver uptake of a wide range of substrates including conjugated and unconjugated bilirubin, xenobiotics and drugs. Absence of OATP1Bs in the liver causes Rotor syndrome. Our aim was to correlate OATP1B expression with hyperbilirubinemia in common liver diseases. METHODS: Immunoreactivity of five antibodies against human OATP1Bs was tested on frozen and formalin-fixed paraffin-embedded liver tissue of mouse strains transgenic for SLCO1B1 or SLCO1B3 and on human specimens. The proportion of hepatocytes expressing OATP1Bs was then assessed immunohistologically in formalin-fixed paraffin-embedded liver samples obtained from patients with hepatocellular and primary biliary liver diseases. UGT1A1 promoter TATA-box and SLCO1B1rs4149056 genotyping was performed to rule out individuals predisposed to hyperbilirubinemia. RESULTS: The most specific detection of OATP1B3 was achieved with the H-52 (sc-98981) antibody. OATP1B1 was specifically recognized with the ESL (ab15441) anti-OATP1B1 antibody, but only in frozen sections. The MDQ (ab15442) anti-OATP1B1 antibody cross-reacted with both OATP1B proteins in liver tissue of the transgenic mouse strains. Expression of the OATP1B proteins was decreased in advanced liver diseases and inversely correlated with serum bilirubin levels. The reduction was more pronounced in advanced primary biliary diseases (1.9±1.1 vs. 2.7±0.6; P=0.009). CONCLUSIONS: Down-regulation of OATP1B proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases.
Authors: Martin G Belinsky; Paul A Dawson; Irina Shchaveleva; Lisa J Bain; Renxue Wang; Victor Ling; Zhe-Sheng Chen; Alex Grinberg; Heiner Westphal; Andres Klein-Szanto; Anthony Lerro; Gary D Kruh Journal: Mol Pharmacol Date: 2005-04-06 Impact factor: 4.436
Authors: T Abe; M Unno; T Onogawa; T Tokui; T N Kondo; R Nakagomi; H Adachi; K Fujiwara; M Okabe; T Suzuki; K Nunoki; E Sato; M Kakyo; T Nishio; J Sugita; N Asano; M Tanemoto; M Seki; F Date; K Ono; Y Kondo; K Shiiba; M Suzuki; H Ohtani; T Shimosegawa; K Iinuma; H Nagura; S Ito; S Matsuno Journal: Gastroenterology Date: 2001-06 Impact factor: 22.682
Authors: Evita van de Steeg; Viktor Stránecký; Hana Hartmannová; Lenka Nosková; Martin Hřebíček; Els Wagenaar; Anita van Esch; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Eva Sticová; Mohammad al-Edreesi; A S Knisely; Stanislav Kmoch; Milan Jirsa; Alfred H Schinkel Journal: J Clin Invest Date: 2012-01-09 Impact factor: 14.808
Authors: Stephan R Vavricka; Diana Jung; Michael Fried; Uwe Grützner; Peter J Meier; Gerd A Kullak-Ublick Journal: J Hepatol Date: 2004-02 Impact factor: 25.083